Ensysce Biosciences Inc Cash Flow Conversion Efficiency
Ensysce Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has a cash flow conversion efficiency ratio of 1.767x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.96 Million) by net assets ($-1.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ensysce Biosciences Inc (2017–2025)
Cash flow conversion efficiency of Ensysce Biosciences Inc from 2017 to 2025. This chart illustrates how Ensysce Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ENSC stock price and chart for real-time trading data and today's change.
Ensysce Biosciences Inc Cash Flow Conversion Ratio Explained
Ensysce Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ensysce Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ensysce Biosciences Inc ranked by their cash flow conversion efficiency. Also see ENSC market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alfa Energi Investama Tbk PT
JK:FIRE
|
0.043x |
|
SEL Manufacturing Company Limited
NSE:SELMC
|
-0.098x |
|
Fastpasscorp A/S
CO:FASTPC
|
0.246x |
|
oodash Group AB (publ)
ST:OODA
|
N/A |
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
-0.456x |
|
Horseshoe Metals Ltd
AU:HOR
|
0.151x |
|
Geoprima Solusi Tbk PT
JK:GPSO
|
-0.036x |
|
ZINC of Ireland NL
AU:ZMI
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Ensysce Biosciences Inc from 2017 to 2025. Review ENSC free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.88 Million | $-7.81 Million | -2.706x | -21.91% |
| 2024-12-31 | $3.38 Million | $-7.50 Million | -2.220x | -113.41% |
| 2023-12-31 | $-651.27K | $-10.78 Million | 16.552x | +272.89% |
| 2022-12-31 | $-4.03 Million | $-17.89 Million | 4.439x | +339.37% |
| 2021-12-31 | $-8.16 Million | $-8.24 Million | 1.010x | +439.31% |
| 2020-12-31 | $-6.66 Million | $-1.25 Million | 0.187x | +217.21% |
| 2019-12-31 | $186.17 Million | $10.99 Million | 0.059x | +1041.43% |
| 2018-12-31 | $197.39 Million | $-1.24 Million | -0.006x | -386.42% |
| 2017-12-31 | $195.27 Million | $-251.83K | -0.001x | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more